CG Oncology's Creto Combination Could Drive Better Efficacy in BCG-Exposed NMIBC, UBS Says

MT Newswires Live05-18

CG Oncology's (CGON) initial data from its phase 2 study support a potential cretostimogene and Gemcitabine combination strategy to drive better efficacy in Bacillus Calmette-Guerin-exposed non-muscle invasive bladder cancer, UBS said in a Monday note.

The firm said that the cretostimogene and Gemcitabine combination showed a clean safety profile with no high-grade treatment-related adverse events, further supporting their combinability.

UBS noted, however, that long-term durability of the combination remains to be seen.

The firm said that the Bacillus Calmette-Guerin-exposed population is an underappreciated opportunity, and continued de-risking efficacy data could drive long-term upside.

UBS has a buy rating on the stock and a $90 price target.

Price: 65.36, Change: -1.58, Percent Change: -2.35

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2636007755?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-18 23:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2636007755","market":"sg","top_or_hot":-1,"title":"CG Oncology's Creto Combination Could Drive Better Efficacy in BCG-Exposed NMIBC, UBS Says","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/CGON\">CG Oncology</a>'s (CGON) initial data from its phase 2 study support a potential cretostimogene and Gemcitabine combination strategy to drive better efficacy in Bacillus Calmette-Guerin-exposed non-muscle invasive bladder cancer, UBS said in a Monday note.</p><p>The firm said that the cretostimogene and Gemcitabine combination showed a clean safety profile with no high-grade treatment-related adverse events, further supporting their combinability.</p><p>UBS noted, however, that long-term durability of the combination remains to be seen.</p><p>The firm said that the Bacillus Calmette-Guerin-exposed population is an underappreciated opportunity, and continued de-risking efficacy data could drive long-term upside.</p><p>UBS has a buy rating on the stock and a $90 price target.</p><p>Price: 65.36, Change: -1.58, Percent Change: -2.35</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CG Oncology's Creto Combination Could Drive Better Efficacy in BCG-Exposed NMIBC, UBS Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCG Oncology's Creto Combination Could Drive Better Efficacy in BCG-Exposed NMIBC, UBS Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-05-18 23:42</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/CGON\">CG Oncology</a>'s (CGON) initial data from its phase 2 study support a potential cretostimogene and Gemcitabine combination strategy to drive better efficacy in Bacillus Calmette-Guerin-exposed non-muscle invasive bladder cancer, UBS said in a Monday note.</p><p>The firm said that the cretostimogene and Gemcitabine combination showed a clean safety profile with no high-grade treatment-related adverse events, further supporting their combinability.</p><p>UBS noted, however, that long-term durability of the combination remains to be seen.</p><p>The firm said that the Bacillus Calmette-Guerin-exposed population is an underappreciated opportunity, and continued de-risking efficacy data could drive long-term upside.</p><p>UBS has a buy rating on the stock and a $90 price target.</p><p>Price: 65.36, Change: -1.58, Percent Change: -2.35</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BCG","symbol_name":"Binah Capital Group Inc","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2636007755","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2636007755","pubTimestamp":1779118941,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"CG Oncology's  initial data from its phase 2 study support a potential cretostimogene and Gemcitabine combination strategy to drive better efficacy in Bacillus Calmette-Guerin-exposed non-muscle invasive bladder cancer, UBS said in a Monday note.The firm said that the cretostimogene and Gemcitabine combination showed a clean safety profile with no high-grade treatment-related adverse events, further supporting their combinability.UBS noted, however, that long-term durability of the combination remains to be seen.The firm said that the Bacillus Calmette-Guerin-exposed population is an underappreciated opportunity, and continued de-risking efficacy data could drive long-term upside.UBS has a buy rating on the stock and a $90 price target.Price: 65.36, Change: -1.58, Percent Change: -2.35","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BCG":"Binah Capital Group Inc","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","BK4139":"生物科技","CG":"凯雷","BK4135":"资产管理与托管银行","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","CGON":"CG Oncology Inc.","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC"},"translate_title":"瑞银表示，CG Oncology的Creto组合可以提高卡介苗暴露的NMIBC的疗效","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BCG":1.5,"CGON":1.5,"CG":1.5},"content_text":"CG Oncology's (CGON) initial data from its phase 2 study support a potential cretostimogene and Gemcitabine combination strategy to drive better efficacy in Bacillus Calmette-Guerin-exposed non-muscle invasive bladder cancer, UBS said in a Monday note.The firm said that the cretostimogene and Gemcitabine combination showed a clean safety profile with no high-grade treatment-related adverse events, further supporting their combinability.UBS noted, however, that long-term durability of the combination remains to be seen.The firm said that the Bacillus Calmette-Guerin-exposed population is an underappreciated opportunity, and continued de-risking efficacy data could drive long-term upside.UBS has a buy rating on the stock and a $90 price target.Price: 65.36, Change: -1.58, Percent Change: -2.35","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2636007755","isCrawlerRequest":true}